Re-purposing Cefepime / Sulbactam as a Precision Treatment for Gram-negative Infections at Queen Mary University of London on FindAPhD.com

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities

Dr D Wareham, Dr O Marches, Dr J Standing No more applications being accepted Funded PhD Project (UK Students Only)

London United Kingdom Bacteriology Microbiology Molecular Biology Pathology Pharmacy

About the Project

Applications are invited from graduates in Microbiology or other relevant biomedical sciences (First or Upper Second) to work with Antimicrobial Research UK (ANTRUK) on Re-purposing β-lactam Combination Therapies as a Precision Treatment for Gram-negative Infections. This 3 year studentship will commence in September 2022 and be based at the Blizard Institute within the School of Medicine and Dentistry.

We have identified a potent synergistic antimicrobial interaction when cefepime is combined with sulbactam against multi-drug resistant Acinetobacter spp and Enterobacterales strains in-vitro (Wareham et, al 2020). Activity of the combination has been confirmed in a national surveillance study (MUTATE) conducted by ANTRUK using a disc diffusion assay developed for rapid susceptibility testing. A pharmacodynamic hollow-fibre dose ranging study is underway (Prof J Standing, UCL Precision Medicine) to determine the optimal formulation for the treatment of MDR Gram-negative infections. Progression of cefepime / sulbactam towards clinical use and a licensed indication requires further studies to inform on dosing, comparative activity, resistance potential, toxicology and clinical efficacy. These issues will be addressed as part of the experimental work to be undertaken in this 3-year PhD studentship.

Interviews to be held on Monday 5th September 2022

To apply, please follow this link: https://mysis.qmul.ac.uk/urd/sits.urd/run/siw_ipp_lgn.login?process=siw_ipp_app&code1=RFQM-W1XF-09&code2=0013

Funding Notes

This 3 year PhD studentship is funded by Queen Mary, University of London in collaboration with Antimicrobial Research UK and comes with a tax-free stipend of £18,489.67 per annum (in the first year). It is open to UK Nationals, EEA/Swiss migrant workers and non-UK nationals with indefinite leave to remain in the UK who will have three years ordinary residence in the EU prior to the start of the studentship. University tuition fees (at UK/EU levels) will be met by the funding body. The project is open to overseas applicants able to self-fund tuition and bench fees.

References

Wareham DW, Momin MHFA, Phee LM, Hornsey M, Standing JF. Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. Journal of Antimicrobial Chemotherapy. 2019 Oct 16. pii: dkz420. doi: 10.1093/jac/dkz420